[Peptide imaging: the somatostatine model]

Maria Rosaria Prisco1, Andrea Vaccaro, Gianluca Gatta

  • 1Seconda Universita Napoli, Napoli. mariarosaria.prisco@hotmail.it

Insights

Radiolabeled peptide receptor-binding molecules are key radiopharmaceuticals for imaging neuroendocrine tumors (NETs). 111In Octreotide is a diagnostic gold standard, with peptide-receptor scintigraphy showing promise in various applications.

Area of Science:

  • Radiopharmaceuticals
  • Molecular Imaging
  • Oncology

Background:

  • Radiolabeled cell-surface peptide receptor-binding molecules represent a significant advancement in radiopharmaceutical development.
  • 111In Octreotide has been a primary tool for functional imaging of neuroendocrine tumors (NETs).
  • In certain tumor types, this approach is considered the diagnostic gold standard.

Purpose of the Study:

  • To review the current status of peptide-receptor scintigraphy in various tumor types.
  • To explore oncologic and non-oncologic applications of this imaging modality.
  • To discuss future developments in the field of peptide-receptor scintigraphy.

Main Methods:

  • Review of current literature on peptide-receptor scintigraphy.
  • Analysis of diagnostic performance in different tumor types.
  • Evaluation of emerging and potential applications.

Main Results:

  • Peptide-receptor scintigraphy, particularly with 111In Octreotide, is a valuable diagnostic tool for NETs.
  • Its utility extends beyond NETs to other oncologic and non-oncologic conditions.
  • Ongoing research is expanding the scope and applications of these radiopharmaceuticals.

Conclusions:

  • Peptide-receptor scintigraphy is a well-established and evolving field in nuclear medicine.
  • Its role in diagnosing and managing various diseases is significant and growing.
  • Future developments promise enhanced diagnostic capabilities and therapeutic applications.